Effect of Mucolytic in treatment of cystic fibrosis

Comparison of the nebulized Mannitol with nebulized Hypertonic saline on pulmonary function in patients with cystic fibrosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180307038994N1

Enrollment

Registered

2018-04-15

Start date

2015-11-22

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis. Cystic fibrosis with pulmonary manifestations

Interventions

Intervention 1: Intervention group 1: Receives soluble mannitol at a concentration of 150 milligram per milliliter at 4 cc twice a day via nebulizer device. Intervention 2: Intervention group 2: Recei

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with cystic fibrosis older than 5 years Ability to perform spirometery

Exclusion criteria

Exclusion criteria: Age less than 5 years

Design outcomes

Primary

Measure	Time frame
Pulmonary function based on spirometry. Timepoint: Spirometry at the beginning of study and at the end of study after two weeks of treatment. Method of measurement: Spirometry device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoud Kiani

Shahid Beheshti University of Medical Sciences

m.kiani@mubabol.ac.ir+98 11 3234 0755

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026